Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Severe acute respiratory syndrome coronavirus 2 (inactivated whole virus) (SARS-CoV-2 (inactivated whole virus))
- Target
- SARS-CoV-2 (inactivated whole virus)
- Molecular classification
- Virus (Betacoronavirus, family Coronaviridae), Pathogen-associated antigen, Other
01
Overview
The SARS-CoV-2 inactivated whole virus is a preparation of the entire COVID-19 virus that has been treated, most commonly with beta-propiolactone, to render it non-infectious while preserving its structural proteins (spike, envelope, membrane, and nucleocapsid) and antigenic properties. This enables it to elicit immune responses that closely mimic natural infection, making it highly suitable for vaccines and laboratory assays. Inactivated virus vaccines have been central to COVID-19 prevention in many regions, with extensive safety protocols ensuring no residual infectivity. The technology is established and widely used for other viruses (e.g., polio, influenza)[2][4][6].
- Other names
- SARS-CoV-2 (inactivated)Inactivated SARS-CoV-2Inactivated COVID-19 virusBeta-propiolactone-inactivated SARS-CoV-2
02
Mechanism of action
Induction of protective immunity When administered as a vaccine, inactivated virus stimulates the immune system to produce neutralizing antibodies against the spike protein and other structural antigens
03
Biological functions
Induction of immune response (triggers both humoral and cellular immunity when administered)Antigenic stimulus (used for antibody production, vaccine development, and diagnostic assay control)
04
Disease associations
Infection (SARS-CoV-2 is causative agent of COVID-19)Other (the inactivated form is used for prevention, not direct causation, of disease)
05
Safety considerations
Incomplete inactivation (risk of live virus contamination if protocols fail, a major consideration in manufacturing)Reactogenicity (possibility of local and systemic adverse events typical of whole-virus vaccines)Potential for limited immune responses in certain populations (e.g., elderly, immunocompromised)
06
Interacting drugs
CoronaVac (Sinovac)
2 more in the full profile.
07
Biomarkers
Neutralizing antibody titers (used to assess protection)Cellular immune responses (measured via T cell assays)
Beyond the preview
Go deeper on Severe acute respiratory syndrome coronavirus 2 (inactivated whole virus) (SARS-CoV-2 (inactivated whole virus)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Severe acute respiratory syndrome coronavirus 2 (inactivated whole virus) (SARS-CoV-2 (inactivated whole virus)).